Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)

被引：0
|
作者：
Horn, L. [1 ]
Wakelee, H. [2 ]
Blumenschein, G. [3 ]
Reckamp, K. [4 ]
Waqar, S. [5 ]
Carter, C. A. [6 ]
Gitlitz, B. J. [7 ]
Infante, J. R. [8 ]
Sanborn, R. E. [9 ]
Neal, J. [2 ]
Gockerman, J. P. [10 ]
Dukart, G. [11 ]
Harrow, K. [11 ]
Liang, C. [11 ]
Gibbons, J. J. [11 ]
Hernandez, J. [12 ]
Newman-Eerkes, T. [12 ]
Lim, L. [12 ]
Lovly, C. [1 ]
机构：
[1] Vanderbilt Ingram Canc Ctr, Thorac Oncol, Nashville, TN USA
[2] Stanford Univ, Med Ctr, Med Oncol, Stanford, CA 94305 USA
[3] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Oncol, Houston, TX 77030 USA
[4] City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA USA
[5] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[6] Natl Naval Med Ctr, Thorac Oncol, Bethesda, MD USA
[7] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA
[8] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[9] Providence Portland Med Ctr, Thorac Oncol Program, Portland, OR USA
[10] Novella Clin, Oncol, Morristown, NC USA
[11] Xcovery Holding Co, Oncon, Palm Beach Gardens, FL USA
[12] Resolut Biosci, Clin Operat, Bellevue, WA USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1210PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC).
    Horn, Leora
    Wakelee, Heather A.
    Reckamp, Karen L.
    Blumenschein, George R.
    Infante, Jeffrey R.
    Carter, Corey Allan
    Waciar, Saiama Naheed
    Neal, Joel W.
    Gockerman, Jon P.
    Harrow, Kimberly
    Dukart, Gary
    Liang, Chris
    Gibbons, James J.
    Hernandez, Jennifer
    Newman-Eerkes, Tara
    Lim, Lee
    Lovly, Christine Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK plus NSCLC
    Horn, Leora
    Wakelee, Heather
    Reckamp, Karen L.
    Blumenschein, George, Jr.
    Infante, Jeffrey R.
    Carter, Corey A.
    Waqar, Saiama N.
    Nea, Joel W.
    Harrow, Kimberly
    Gockerman, Jon P.
    Dukart, Gary
    Liang, Chris
    Gibbons, James L.
    Hernandez, Jennifer
    Newman-Eerkes, Tera
    Lim, Lee
    Lovly, Christine M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S256 - S257
  • [3] Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC
    Horn, Leora
    Wakelee, Heather
    Reckamp, Karen
    Blumenschein, George
    Infante, Jeffrey
    Carter, Corey
    Waqar, Saiama
    Neal, Joel
    Gockerman, Jon
    Harrow, Kimberly
    Dukart, Gary
    Liang, Chris
    Gibbons, James
    Hernandez, Jennifer
    Newman-Eerkes, Tera
    Lim, Lee
    Lovly, Christine
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1159 - S1159
  • [4] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Reckamp, Karen L.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Wakelee, Heather
    Carter, Corey A.
    Gockerman, Jon P.
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S36 - S37
  • [5] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Lovly, Christine M.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Reckamp, Karen
    Wakelee, Heather
    Carter, Corey A.
    VVagar, Saiama N.
    Neal, Joel
    Gockerman, Jon P.
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    CANCER RESEARCH, 2016, 76
  • [6] Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK plus NSCLC
    Leal, Ticiana
    Wakelee, Heather
    Infante, Jeffrey
    Blumenschein, George
    Reckamp, Karen
    Carter, Corey
    Waqar, Saiama
    Gockerman, Jon
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S209 - S210
  • [7] Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
    Horn, Leora
    Infante, Jeffrey R.
    Reckamp, Karen L.
    Blumenschein, George R.
    Leal, Ticiana A.
    Waqar, Saiama N.
    Gitlitz, Barbara J.
    Sanborn, Rachel E.
    Whisenant, Jennifer G.
    Du, Liping
    Neal, Joel W.
    Gockerman, Jon P.
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Holzhausen, Allison
    Lovly, Christine M.
    Wakelee, Heather A.
    CLINICAL CANCER RESEARCH, 2018, 24 (12) : 2771 - 2779
  • [8] EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
    Horn, L.
    Wu, Y-L.
    Reck, M.
    Liang, C.
    Tan, F.
    Harrow, K.
    Oertel, V.
    Dukart, G.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
    Horn, Leora
    Wu, Yi-Long
    Reck, Martin
    Liang, Chris
    Tan, Fenlai
    Harrow, Kimberly
    Oertel, Vance
    Dukart, Gary
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial.
    Bazhenova, Lyudmila
    Gettinger, Scott N.
    Langer, Corey J.
    Salgia, Ravi
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Haney, Jeff
    Rivera, Victor M.
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345